Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: Analysis of Economic Data from the CLARITY Study

Author： Ali Shehzad  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.32, Iss.1, 2012-01, pp. : 15-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo   Hartung Hans-Peter   Kurukulasuriya Nuwan C   Greenberg Steven J   Scaramozza Matthew  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis

By Muir Victoria J.   Plosker Greg L.  

CNS Drugs, Vol. 25, Iss. 3, 2011-03 ,pp. : 239-249

Adis International

Access to resources Recommend Favorite

Emerging oral drugs for relapsing–remitting multiple sclerosis

By Gasperini Claudio   Ruggieri Serena  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 697-712

Informa Healthcare

Access to resources Recommend Favorite

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

By Russo P.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

By  

Current Neuropharmacology, Vol. 12, Iss. 3, 2014-05 ,pp. : 256-268

Bentham Science Publishers

Access to resources Recommend Favorite